Answers are grounded in this paper and cite their sources.
Retrospective analysis shows consistent safety profiles for onabotulinumtoxinA in patients with chronic migraine and other conditions, suggesting no new safety signals.
TEAEs associated with onabotulinumtoxinA treatment in adults with CM and ≥ 1 coexisting disease within 3 months were generally consistent with the known safety profiles for the individual onabotulinumtoxinA indications. There were no new safety signals observed for up to 6 months after multi-indication treatment.
No takes yet. Share an insight, caveat, or question.
Blumenfeld et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: